This human stem cell portfolio includes hematopoietic CD34+ stem cell products as well as pluripotent stem cells.
Hematopoietic CD34+ stem cells are available from three sources: mobilized peripheral blood, bone marrow, or cord blood. Mobilized CD34+ stem cells are collected after G-CSF, Plerixafor or G-CSF/Plerixafor is administered to healthy consented donors. Bone marrow aspirate is drawn from the posterior iliac crest from healthy donors and CD34+ stem/progenitor cells and mesenchymal stem cells are then isolated. Cord blood CD34+ stem cells are isolated from human cord blood that is collected at the time of delivery from healthy pregnant women.
Partnering with pluristyx to offer a portfolio of human-derived pluripotent stem cells for research use only, which includes induced pluripotent stem cells (iPSCs) and embryonic stem cells (ES cells). These pluripotent stem cells have an unlimited capacity for self-renewal and the potential to differentiate into every cell type in the body. This portfolio provides access to wild-type iPSCs, a genetically modified iPSC line containing FailSafe® technology with an HSV-TK suicide gene knock-in system, normal embryonic cells, and diseased embryonic stem cell lines.
Bone marrow aspirate: Human bone marrow aspirate contains a large concentration of primitive CD34+ hematopoietic stem cells as well as mesenchymal stem cells. It is utilized in the development of cell-based therapies and regenerative medicine for the treatment of various disease types, including blood disorders and other immune or genetic diseases. The bone marrow aspirate is drawn from the posterior iliac crest from healthy human donors who have consented under an IRB-approved protocol.
Please contact an Avantor sales representative or Life Sciences Specialist for assistance with this fresh product order.
Ordering information: Product is made to order.
Delivery information: Cold packs, ambient temperature 2 to 8 °C or 15 to 25 °C.
Packaging: Collection bag.
Caution: For research use only.